Recursion

What it does

Recursion Pharmaceuticals is a techbio company that combines AI, massive biological datasets, and laboratory automation to accelerate drug discovery - operating one of the world's largest biological imaging datasets and using AI to identify drug candidates. Recursion's OS (operating system) platform enables partnerships with pharmaceutical companies to apply AI-driven biological experimentation to specific disease programs. AI capabilities include deep learning biological image analysis that identifies cellular phenotypes from high-content imaging experiments, ML drug-disease interaction prediction that identifies promising drug-target combinations from biological data, AI compound activity prediction that ranks molecules by likelihood of therapeutic effect, multi-omics data integration that correlates genetic, transcriptomic, and phenotypic datasets for drug mechanism understanding, and automated experimental design that plans efficient biological experiments.

Strengths

• Large pharmaceutical companies partner with Recursion for AI drug discovery programs - applying Recursion's AI biological platform and datasets to specific therapeutic area programs.
• Recursion Pharmaceuticals is a techbio company that combines AI, massive biological datasets, and laboratory automation to accelerate drug discovery - operating one of the world's largest biological imaging datasets and using AI to identify drug candidates.
• Recursion's OS (operating system) platform enables partnerships with pharmaceutical companies to apply AI-driven biological experimentation to specific disease programs.

Watch-outs

• Techbio company — not a commercial software product: Recursion operates as a drug discovery company using AI rather than selling AI drug discovery software — pharmaceutical companies engage Recursion through partnerships rather than licensing software.
• AI drug discovery is still unproven at scale in clinical translation: Recursion's AI-discovered candidates must progress through clinical trials before validating the platform's ability to identify successful drugs — AI drug discovery remains an emerging capability rather than proven approach.
• Competes with Schrödinger, Exscientia, and Insilico Medicine: Multiple AI-first drug discovery companies compete in this space — pharmaceutical partners evaluate biological data breadth, AI model accuracy, and clinical track record when selecting AI drug discovery collaborators.

Pricing

Recursion operates through research collaborations and partnerships. Commercial partnership terms negotiated with pharmaceutical companies.